优势价格
快速发货
品质保证
技术支持
400-920-2911 sales@csnpharm.cn
VEGFR
| 货号 | 产品名 | CAS号 | 信息 |
|---|---|---|---|
| CSN18068 | ZM323881 HCl | 193000-39-4 | ZZZM 323881 HCl is a potent and selective VEGFR2 inhibitor with IC50 of < 2 nM, almost no activity on VEGFR1, PDGFRβ, FGFR1, EGFR and ErbB2. |
| CSN16611 | ZM323881 | 193001-14-8 | ZZM 323881 is a potent and selective VEGFR2 inhibitor with IC50 of < 2 nM, exhibiting almost no activity on VEGFR1, PDGFRβ, FGFR1, EGFR and ErbB2. |
| CSN20194 | α-Cembrenediol | 57605-80-8 | VEGFR inhibitor TC1 acts in angiogenesis inhibitory in multiple breast cancer cell lines by significantly reducing the activated VEGFR2 levels. |
| CSN16730 | Vatalanib | 212141-54-3 | Vatalanib is an inhibitor of VEGFR2/KDR with IC50 of 37 nM, showing less potent against VEGFR1/Flt-1, 18-fold against VEGFR3/Flt-4. |
| CSN12454 | Vatalanib 2HCl | 212141-51-0 | Vatalanib 2HCl is inhibitor of VEGFR2 or KDR with IC50 of 37 nM. |
| CSN12186 | N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine | 443913-73-3 | Vandetanib is a potent inhibitor of VEGFR2 with IC50 of 40 nM. |
| CSN18225 | Vandetanib trifluoroacetate | 338992-53-3 | Vandetanib is a potent inhibitor of VEGFR2 with IC50 of 40 nM. |
| CSN18317 | N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine hydrochloride | 524722-52-9 | Vandetanib HCl specially inhibits VEGFR2 with IC50 of 40 nM. |
| CSN21277 | Tyrosine kinase-IN-1 | 705946-27-6 | Tyrosine kinase-IN-1 is a multi-targeted tyrosine kinase inhibitor with IC50s of 4, 20, 4, 2 nM for KDR, Flt-1, FGFR1 and PDGFRα, respectively. |
| CSN12667 | Tivozanib | 475108-18-0 | Tivozanib is an inhibitor of VEGFR1, VEGFR2 and VEGFR3 with IC50s of 30 nM, 6.5 nM, 15 nM, respectively. It can also inhibit PDGFR and c-Kit. |
| CSN17394 | TG 100801 HCl | 1018069-81-2 | TG 100801 is the prodrug of TG 100572, which is a multi-targeted kinase inhibitor that inhibit select growth factor receptor tyrosine kinases and Src familt kinases with IC50 values of 2/7/2/1/0.5 nM or VEGFR1/VEGFR2/FGFR1/Src/Fyn kianse respectively. |
| CSN12041 | Telatinib | 332012-40-5 | Telatinib is a potent inhibitor of VEGFR2/3, c-Kit and PDGFRα with IC50 of 6 nM/4 nM, 1 nM and 15 nM, respectively. |
| CSN15808 | 3-((3,5-Dimethyl-1H-pyrrol-2-yl)methylene)indolin-2-one | 204005-46-9 | SU5416 is a selective VEGFR2 (Flk-1/KDR) inhibitor with IC50 of 1.23 μM. |
| CSN12658 | SU 5402 | 215543-92-3 | SU5402 is potent and selective vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR) inhibitor. |
| CSN20282 | Su-10994 | 748153-84-6 | SU-10994 is a VEGFR inhibitor with potential anticancer activity. |
| CSN17169 | 2-((6,7-Dimethoxyquinazolin-4-yl)thio)-5-methyl-1,3,4-thiadiazole | 1225451-84-2 | SKLB1002 is a selective inhibitor of VEGFR2 with IC50 of 32 nM. |
| CSN15794 | (Z)-3-((3,5-Dimethyl-1H-pyrrol-2-yl)methylene)indolin-2-one | 194413-58-6 | Semaxanib is an inhibitor of VEGFR2 (namely Flk-1 or KDR) with IC50 of 1.23 μM. |
| CSN17854 | SAR131675 | 1433953-83-3 | SAR131675 is selective inhibitor of VEGFR3 with IC50 and Ki of 23 nM, 12 nM, respectively. |
| CSN17331 | 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide hydrate | 1019206-88-2 | Regorafenib is a multi-target inhibitor. It can inhibit the activities of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 and their IC50 values range from 1.5 nM to 46 nM. |
| CSN17185 | 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide hydrochloride | 835621-07-3 | Regorafenib HCl can inhibit many kinases including RET (IC50 = 1.5 nM), Raf-1 (IC50 = 2.5 nM), VEGFR2 (IC50 = 4.2 nM), VEGFR1 (IC50 = 13 nM), PDGFRβ (IC50 = 22 nM) and VEGFR3 (IC50 = 46 nM). |
| CSN16062 | RAF265 | 927880-90-8 | RAF265 is a pan-inhibitor that inhibits C-Raf, B-Raf and B-Raf V600E with IC50 of 3 nM-60 nM. It also shows inhibition on phosphorylation of VEGFR2 with EC50 of 30 nM. |
| CSN18523 | R1530 | 882531-87-5 | R1530 is the multikinase inhibitor with potential antiangiogenesis and antineoplastic activities. |
| CSN13729 | 5-((4-((2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-2-yl)amino)-2-methylbenzenesulfonamide hydrochloride | 635702-64-6 | Pazopanib HCl is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively. |
| CSN11151 | Oglufanide | 38101-59-6 | Oglufanide is inhibitor of vascular endothelial growth factor (VEGF) that suppresses angiogenesis. |
| CSN12341 | Methyl (Z)-3-(((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(phenyl)methylene)-2-oxoindoline-6-carboxylate | 656247-17-5 | Nintedanib is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50 of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM. |
| CSN18236 | N-Desethyl Sunitinib | 356068-97-8 | N-desethyl sunitinib is a major and pharmacologically active metabolite of sunitinib, which is potent, ATP-competitive VEGFR, PDGFRβ and KIT inhibitor (Ki values are 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFRβ and KIT respectively). |
| CSN12691 | Motesanib | 453562-69-1 | Motesanib is an ATP-competitive inhibitor of VEGFR1 (IC50 = 2 nM), VEGFR2 (IC50 = 3 nM), VEGFR3 (IC50 = 6 nM) and Kit. |
| CSN17192 | Motesanib Diphosphate | 857876-30-3 | Motesanib diphosphate is ATP-competitive inhibitor of VEGFR1, VEGFR2 and VEGFR3 with IC50 of 2 nM, 3 nM and 6 nM, respectively. It also shows better inhibitory activity against c-Kit, PDGFR, and RET. |
| CSN13151 | MGCD-265 analog | 875337-44-3 | MGCD-265, an ATP-competitive inhibitor, can inhibit c-Met and VEGFR1, 2, 3 with IC50s of 1 nM and 3 nM, 3 nM, 4 nM, respectively. It also exhibits inhibition of Ron and Tie2. |
| CSN15974 | 4-(3-Chloro-4-(3-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide | 417716-92-8 | Lenvatinib is a multi-target inhibitor, mostly for VEGFR2 (KDR)/VEGFR3 (Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold selective for VEGFR2/3 against FGFR1, PDGFRα/β. |
| CSN15848 | KRN-633 | 286370-15-8 | KRN-633 can inhibit VEGFR1, VEGFR2 and VEGFR3 with IC50 of 170 nM, 160 nM, and 125 nM, respectively. |
| CSN17193 | Ki8751 | 228559-41-9 | Ki8751 is a selective VEGFR2 inhibitor with IC50 of 0.9 nM. |
| CSN17542 | Fruquintinib | 1194506-26-7 | Fruquintinib is an inhibitor of VEGFR family with IC50s of 33 nM, 35 nM and 0.5 nM for VEGFR1, 2, 3 respectively. |
| CSN17568 | EG00229 | 1210945-69-9 | EG00229 is the first small molecule inhibitor of the neuropilin-1 and VEGF-A interaction with an IC50 of inhibition of 8 μM(125I-VEGF binding to PAE/NRP1 cells). |
| CSN17438 | Lucitanib | 1058137-23-7 | E-3810 is a dual inhibitor of the VEGF and FGF receptors, potently and selectively inhibits VEGFR1, VEGFR2, VEGFR3, FGFR1 and FGFR2 with IC50 of 7 nM, 25 nM, 10 nM, 17.5 nM, and 82.5 nM, respectively. |
| CSN13440 | CP-547632 | 252003-65-9 | CP-547632 is a potent inhibitor of the VEGFR-2 and basic fibroblast growth factor (FGF) kinases (IC50 11 and 9 nM, respectively). It is selective relative to epidermal growth factor receptor, platelet-derived growth factor, and other related TKs. It also inhibits VEGF-stimulated autophosphorylation of VEGFR-2 in a whole cell assay with an IC50 value of 6 nM. |
| CSN17311 | Cediranib maleate | 857036-77-2 | Cediranib maleate is a highly potent VEGFR (KDR) inhibitor with IC50 of < 1 nM, also inhibits Flt1/4 with IC50 of 5 nM/≤3 nM, similar activity against c-Kit and PDGFRβ, 36-, 110-fold and > 1000-fold selective more for VEGFR than PDGFR-α, CSF-1R and Flt3. |
| CSN16877 | N-(4-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (S)-2-hydroxysuccinate | 1140909-48-3 | Cabozantinib S-malate is a VEGFR2 inhibitor with IC50 of 0.035 nM. It also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM-11.3 nM. |
| CSN12669 | Brivanib | 649735-46-6 | Brivanib is an ATP-competitive inhibitor against VEGFR2 with IC50 of 25 nM, moderate potency against VEGFR-1 and FGFR-1, but > 240-fold against PDGFR-β. |
| CSN13568 | Brivanib (alaninate) | 649735-63-7 | Brivanib alaninate is an ATP-competitive inhibitor against VEGFR2 with IC50 of 25 nM, moderate potency against VEGFR-1 and FGFR-1, but > 240-fold against PDGFR-β. |
| CSN18663 | (3-((4-((2-Amino-3-chloropyridin-4-yl)oxy)-3-fluorophenyl)carbamoyl)-5-(4-fluorophenyl)-4-oxopyridin-1(4H)-yl)methyl dihydrogen phosphate | 1174161-69-3 | BMS-798433 shows greater than 50% TGI for at least one tumor doubling time with no toxicity observed during 14 days in GTL-16 human gastric tumor xenografts model. |
| CSN16881 | (Z)-Methyl 3-(((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(phenyl)methylene)-2-oxoindoline-6-carboxylate ethanesulfonate | 656247-18-6 | BIBF 1120 esylate is a multiple receptor tyrosine kinases inhibitors for VEGFR1/2/3, PDGFRα/β and FGFR1/2/3 with IC50 of 34 nM/13 nM/13 nM, 59 nM/65 nM and 69 nM/37 nM/108 nM. |
| CSN19151 | BFH772 | 890128-81-1 | BFH772 selectively targets VEGFR2 kinase with IC50 of 3 nM. |
| CSN19152 | NVP-BAW2881 | 861875-60-7 | BAW2881 is an inhibitor of vascular endothelial growth factor (VEGF) with IC50s of 1.0 nM-4.3 nM against VEGFR1, 2, 3 and also inhibits PDGFRβ, c-Kit, and RET. |
| CSN18525 | AZD2932 | 883986-34-3 | AZD2932 is a series of quinazoline ether inhibitor which potently inhibits VEGFR-2 and PDGFR with IC50s of 4 nM/8 nM/ 7 nM for PDGFRβ/VEGFR-2/Flt-3. |
| CSN17579 | N-(4-(1-Cyanocyclopentyl)phenyl)-2-((pyridin-4-ylmethyl)amino)nicotinamide methanesulfonate | 1218779-75-9 | Apatinib Mesylate is a VEGFR2 inhibitor with IC50 of 1 nM and also can suppress the activities of Ret (IC50 = 13 nM), c-Kit (IC50 = 429 nM) and c-Src (IC50 = 530 nM). |
| CSN13818 | N-(4-(1-Cyanocyclopentyl)phenyl)-2-((pyridin-4-ylmethyl)amino)nicotinamide | 811803-05-1 | Apatinib is a selective inhibitor of VEGFR2 with IC50 of 1 nM. |
| CSN16990 | VEGFR-2-IN-5 | 1430089-64-7 | 2,4-Pyrimidinediamine with linker is a multikinase inhibitor with a -NH2 terminal linker. |
